Abstract:Background: The aim of this study was to investigate and discuss the salbutamol combined with budesonide in treatment of pediatric bronchial asthma (BA) and its effect on eosinophils (EOS). Methods: Ninety-eight BA children admitted and treated in our hospital from July 2016 to June 2017 were collected and divided into control group (N.=49) and observation group (N.=49) according to random number table. The children in control group were treated with budesonide and those in observation group were treated with salbutamol combined with budesonide. The clinical efficacy, pulmonary functions and levels of T-lymphocyte subsets (including cluster of differentiation 3 (CD3)+, CD4+, CD8+ and CD4+/CD8+) in the immune system between two groups were compared after the treatment; the levels of eosinophil cationic protein (ECP) and eotaxin in the children were compared before the treatment and at 1, 4 and 8 weeks after the treatment; the changes in EOS counts in blood and induced sputum of the children before and after the treatment were compared, and the EOS apoptosis rate was compared at 1, 4 and 8 weeks after the treatment. Results: The effective rate of treatment in observation group was significantly higher than that in control group (P<0.05). After the treatment, the indexes of pulmonary function in observation group were obviously better than those in control group (P<0.05). Compared with those in control group, the levels of CD3+, CD4+ and CD4+/CD8+ of the children in observation group were elevated remarkably, while the CD8+ level was lowered (P<0.05). The levels of ECP and eotaxin in the two groups were decreased after the treatment compared with those before the treatment, and the levels in observation group were superior to those in control group (P<0.05). After the treatment, the EOS counts of both groups of children were lower than those before the treatment, and the decrease in observation group was more notable than that in control group. At 1, 4 and 8 weeks after the treatment, the EOS apoptosis rate in observation group was obviously higher than that in control group (P<0.05). Conclusions: The treatment of salbutamol combined with budesonide for pediatric BA has significant therapeutic effects; it can restore the pulmonary functions rapidly and improve the immunity of the lung, reduce the levels of eotaxin, ECP and EOS of the child patients and promote EOS apoptosis.

Effect of of Jinshuibao capsules combined with Salmeterol Fluticasone Propionate Powder inhalation on clinical efficacy, lung function and cellular immune factors in patients with bronchial asthma

Clinical study on Pingfeng Shengmai Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Aerosol in treatment of bronchial asthma

Efficacy of Fluticasone and Salmeterol Dry Powder in Treating Patients with Bronchial Asthma and Its Effect on Inflammatory Factors and Pulmonary Function

Effects of budesonide formoterol combined with Bailing capsule on airway remodeling and immune function in patients with bronchial asthma

Influence Analysis of Salmeterol Fluticasone and Budesonide to Lung Function of Patients with Bronchial Asthma

Clinical Efficacy of Budesonide and Formoterol Fumarate Powder in the Treatment of Patients with Bronchial Asthma and Its Effect on the Serum Levels of Inflammatory Factors

Effects of budesonide combined with salbutamol on pulmonary function and peripheral blood eosinophiles and IgE in patients with acute attack of bronchial asthma

Salbutamol combined with budesonide in treatment of pediatric bronchial asthma and its effect on eosinophils

Clinical Evaluation of Different Doses of Salmeterol and Fluticasone in Adjuvant Treatment of Bronchial Asthma

Efficacy of tiotropium bromide combined with different doses of fluticasone plus salmeterol DPI in the treatment of stable COPD

Effect of budesonide formoterol combined with tiotropium bromide on pulmonary function and inflammatory factors in patients with asthma-COPD overlap syndrome

A Randomized Comparative Trial of Clarithromycin Combined Regimens Containing Salmeterol/Fluticasone for Treatment of Bronchial Asthma

[Combination of Inhaled Salmeterol/fluticasone and Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease: a Randomised Controlled Trial].

Salmeterol/fluticasone Combined with N-acetylcysteine in Treatment of Airway Inflammation of Stable Chronic Obstructive Pulmonary Disease

Budesonide/Fomoterol in combination with Montelukast in the treatment of Bronchial Asthma.

Combined Inhaled Corticosteroid and Long-Acting Β2-Adrenergic Agonist Therapy for Noncystic Fibrosis Bronchiectasis with Airflow Limitation

Efficacy of Salmeterol/fluticasone Propionate and Tiotropium in Patients with Stable Stage of Group D COPD

Effect Observation of 115 Children with Asthma Treated with Salmeterol/flutieasone Propionate Inhalation

Observation on the clinical efficacy of tiotropium combined with formoterol and salmeterol in the treatment of patients with chronic obstructive pulmonary disease

Clinical curative effect of salmeterol fluticasone in asthma therapy and its influence on lung function and serum CRP

Effect and Its Side Effects of Long-Term Inhalation of Different Doses of Salmeterol/fluticasone on Moderate to Severe Stable Chronic Obstructive Pulmonary Disease Patients' Airway Inflammation and Physiological Function